Lanreotide and Octreotide LAR for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis
Phase of Trial: Phase IV
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Lanreotide (Primary) ; Octreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Sponsors Ipsen
- 28 Aug 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
- 28 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
- 17 Feb 2017 Status changed from not yet recruiting to recruiting.